Cd40-targeted antibodies and uses thereof
By developing antibodies or antigen-binding fragments that specifically bind to CD40 and bind to co-stimulatory receptors of immune effector cells, the problem of immune escape in immunotherapy for solid tumors has been solved, the anti-tumor activity of T cells has been enhanced, and the therapeutic effects of cancer and chronic infections have been improved.
CN122249462APending Publication Date: 2026-06-19UTC THERAPEUTICS (SHANGHAI) CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- UTC THERAPEUTICS (SHANGHAI) CO LTD
- Filing Date
- 2024-11-04
- Publication Date
- 2026-06-19
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
This document discloses antibodies targeting CD40 and their uses. It also discloses novel antigen-binding proteins capable of specifically binding to CD40 and their antigen-binding fragments. Furthermore, this document discloses fusion proteins comprising a first domain activating antigen-presenting cells (APCs) (e.g., dendritic cells) and a second domain activating immune effector cells (e.g., T cells), wherein the first domain comprises the antigen-binding protein or its antigen-binding fragment that specifically binds to CD40 disclosed herein.
Need to check novelty before this filing date? Find Prior Art